ReviewCritical reviews in oncology/hematology2018
Sarcoma-The standard-bearer in cancer discovery.
Review in Critical reviews in oncology/hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Beyond the benign: A rare case report of myxoid pleomorphic liposarcoma.Radiology case reports · 2025Article
- Epidemiology of Soft Tissue Sarcoma in Iran: Four-Year National Cancer Registry Data Report (2014-2017).Cancer reports (Hoboken, N.J.) · 2025Article
- Unveiling the Role of DPYS: A New Prognostic Biomarker in Sarcoma.Current protein & peptide science · 2025Article
- Evaluating Circulating Biomarkers for Diagnosis, Prognosis, and Tumor Monitoring in Pediatric Sarcomas: Recent Advances and Future Directions.Biomolecules · 2024Review
- Deciphering the role of sphingolipid metabolism in the immune microenvironment and prognosis of esophageal cancer via single-cell sequencing and bulk data analysis.Discover oncology · 2024Article
- Review
- Naturally occurring canine sarcomas: Bridging the gap from mouse models to human patients through cross-disciplinary research partnerships.Frontiers in oncology · 2023Review
- Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas.International journal of molecular sciences · 2022Article
- Oncostatin M Receptor as a Therapeutic Target for Radioimmune Therapy in Synovial Sarcoma.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma.Cancers · 2021Article
- Article
- RNA Sequencing for Personalized Treatment of Metastatic Leiomyosarcoma: Case Report.Frontiers in oncology · 2021Article
- Assessment of Synergistic Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Sarcoma.Molecular diagnosis & therapy · 2020Review
- Cancer Stem Cells in Soft-Tissue Sarcomas.Cells · 2020Review
- Intraoperative radiotherapy with low energy x-rays for primary and recurrent soft-tissue sarcomas.Radiation oncology (London, England) · 2020Article
- CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets.International journal of molecular sciences · 2020Review
- Identification of Subtype-Specific Metastasis-Related Genetic Signatures in Sarcoma.Frontiers in oncology · 2020Article
- Immunotherapeutic strategies for sarcoma: current perspectives.American journal of translational research · 2020Review
- Expressions of miR-21 and miR-210 in Breast Cancer and Their Predictive Values for Prognosis.Iranian journal of public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Sarcoma is a rare tumor type that occurs most frequently in connective tissue. Despite its uncommon occurrence, sarcoma research has provided the means for groundbreaking research that has advanced our understanding of general cancer mechanisms. It is through sarcoma research that the pioneering efforts of cancer immunotherapy were explored, that we understand the inherent genetic nature of cancer mutations, and that we appreciate the subclassification of general cancer types to make more accurate prognoses. This review explores the brief history of sarcoma research and what sarcomas can still teach us about the future of cancer research, especially in regard to novel immunotherapy targets, the role of epigenetics in disease progression and chemoresistance, and the benefits of more focused clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.